MX2021011703A - Composiciones y métodos para alterar el fenotipo de macrófagos. - Google Patents
Composiciones y métodos para alterar el fenotipo de macrófagos.Info
- Publication number
- MX2021011703A MX2021011703A MX2021011703A MX2021011703A MX2021011703A MX 2021011703 A MX2021011703 A MX 2021011703A MX 2021011703 A MX2021011703 A MX 2021011703A MX 2021011703 A MX2021011703 A MX 2021011703A MX 2021011703 A MX2021011703 A MX 2021011703A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- therapeutic agent
- macrophage phenotype
- metal ion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000002540 macrophage Anatomy 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229910021645 metal ion Inorganic materials 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 210000004981 tumor-associated macrophage Anatomy 0.000 abstract 2
- -1 Cu(II) ions Chemical class 0.000 abstract 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 abstract 1
- 229960004891 lapatinib Drugs 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824853P | 2019-03-27 | 2019-03-27 | |
| PCT/US2020/025326 WO2020198622A1 (en) | 2019-03-27 | 2020-03-27 | Compositions and methods for altering macrophage phenotype |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011703A true MX2021011703A (es) | 2022-01-06 |
Family
ID=72606452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011703A MX2021011703A (es) | 2019-03-27 | 2020-03-27 | Composiciones y métodos para alterar el fenotipo de macrófagos. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11590236B2 (https=) |
| EP (1) | EP3946473A4 (https=) |
| JP (1) | JP7665206B2 (https=) |
| BR (1) | BR112021019187A2 (https=) |
| CA (1) | CA3134974A1 (https=) |
| IL (1) | IL286678B2 (https=) |
| MX (1) | MX2021011703A (https=) |
| WO (1) | WO2020198622A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021019187A2 (pt) * | 2019-03-27 | 2021-12-21 | Navidea Biopharmaceuticals Inc | Método para repolarização de um macrófago associado a tumor de m2 a m1, e, composto para repolarização de um macrófago associado a tumor de m2 a m1 |
| US20210052639A1 (en) * | 2019-08-19 | 2021-02-25 | Navidea Biopharmaceuticals, Inc. | Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells |
| JP2025517414A (ja) * | 2022-05-20 | 2025-06-05 | ナビディア、バイオファーマスーティカルズ、インコーポレイテッド | 分解性リンカーを介して新規ビスホスホネート薬物ペイロードを担持するｃｄ２０６標的化薬物送達ビヒクル |
| WO2024076988A2 (en) * | 2022-10-03 | 2024-04-11 | Navidea Biopharmaceuticals, Inc. | Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers |
| CN116259757B (zh) * | 2023-02-06 | 2026-01-30 | 西北大学 | MXene改性的金属离子预嵌入V5O12·6H2O复合材料及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6218367B1 (en) * | 1998-09-15 | 2001-04-17 | Organomed Corporation | Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations |
| CN101801462A (zh) | 2007-07-13 | 2010-08-11 | 健泰科生物技术公司 | 用于癌症、炎性病症和自身免疫性病症的治疗和诊断 |
| WO2013057281A2 (en) | 2011-10-21 | 2013-04-25 | Transgene Sa | Modulation of macrophage activation |
| CN114377143A (zh) * | 2013-07-22 | 2022-04-22 | 康德乐健康414有限责任公司 | 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒 |
| CA2955438C (en) | 2014-07-17 | 2024-07-02 | Ohio State Innovation Foundation | DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR |
| US10806803B2 (en) * | 2014-07-17 | 2020-10-20 | Ohio State Innovation Foundation | Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis |
| WO2016011419A1 (en) * | 2014-07-17 | 2016-01-21 | Ohio State Innovation Foundation | Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis |
| WO2016118188A1 (en) * | 2015-01-21 | 2016-07-28 | Navidea Biopharmaceuticals, Inc. | Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells |
| MX2019004029A (es) * | 2016-10-07 | 2019-09-27 | Navidea Biopharmaceuticals Inc | Compuestos y metodos para diagnosis y tratamiento de infecciones virales. |
| EP3522899A4 (en) * | 2016-10-07 | 2020-05-06 | Navidea Biopharmaceuticals, Inc. | Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same |
| CA3064277A1 (en) | 2017-05-19 | 2018-11-22 | Navidea Biopharmaceuticals, Inc. | Cd206+ macrophage-specific molecular imaging probe compositions and methods and the noninvasive quantification of arterial wall macrophage infiltration in humans |
| US20210000920A1 (en) * | 2017-12-22 | 2021-01-07 | Atossa Therapeutics, Inc. | Intraductal methods of treatment of breast disorders |
| BR112021019187A2 (pt) * | 2019-03-27 | 2021-12-21 | Navidea Biopharmaceuticals Inc | Método para repolarização de um macrófago associado a tumor de m2 a m1, e, composto para repolarização de um macrófago associado a tumor de m2 a m1 |
| US20210052639A1 (en) * | 2019-08-19 | 2021-02-25 | Navidea Biopharmaceuticals, Inc. | Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells |
-
2020
- 2020-03-27 BR BR112021019187A patent/BR112021019187A2/pt unknown
- 2020-03-27 WO PCT/US2020/025326 patent/WO2020198622A1/en not_active Ceased
- 2020-03-27 JP JP2021557633A patent/JP7665206B2/ja active Active
- 2020-03-27 CA CA3134974A patent/CA3134974A1/en active Pending
- 2020-03-27 MX MX2021011703A patent/MX2021011703A/es unknown
- 2020-03-27 EP EP20779897.6A patent/EP3946473A4/en active Pending
- 2020-03-27 IL IL286678A patent/IL286678B2/en unknown
- 2020-03-27 US US16/832,620 patent/US11590236B2/en active Active
-
2023
- 2023-02-27 US US18/174,783 patent/US20230218770A1/en not_active Abandoned
-
2025
- 2025-07-03 US US19/259,342 patent/US20250325681A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL286678B2 (en) | 2025-07-01 |
| US11590236B2 (en) | 2023-02-28 |
| US20250325681A1 (en) | 2025-10-23 |
| US20230218770A1 (en) | 2023-07-13 |
| EP3946473A1 (en) | 2022-02-09 |
| IL286678B1 (en) | 2025-03-01 |
| US20200306381A1 (en) | 2020-10-01 |
| IL286678A (en) | 2021-10-31 |
| CA3134974A1 (en) | 2020-10-01 |
| JP2022527176A (ja) | 2022-05-31 |
| WO2020198622A1 (en) | 2020-10-01 |
| JP7665206B2 (ja) | 2025-04-21 |
| EP3946473A4 (en) | 2023-07-05 |
| BR112021019187A2 (pt) | 2021-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011703A (es) | Composiciones y métodos para alterar el fenotipo de macrófagos. | |
| WO2020236825A8 (en) | Mcl-1 inhibitor antibody-drug conjugates and methods of use | |
| NZ775660A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| WO2017079746A3 (en) | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer | |
| UA103614C2 (uk) | Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки | |
| HK1259311A1 (zh) | Sstr靶向綴合物及其顆粒和製劑 | |
| PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| MX2019004963A (es) | Conjugados y particulas especificos del sstr y formulaciones de los mismos. | |
| WO2017210246A3 (en) | Penicillamine conjugates and particles and formulations thereof | |
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| MX2023013225A (es) | Inhibidores de la cinasa 4 similar a polo. | |
| ZA202101990B (en) | Sulfomaleimide-based linkers and corresponding conjugates | |
| MX2022012544A (es) | Liberacion dirigida de un inhibidor de mir-21 a macrofagos para el tratamiento de la fibrosis pulmonar. | |
| WO2019147338A3 (en) | Radiopharmaceuticals and methods of use thereof | |
| TW200735859A (en) | Methods of treating cancers with SAHA, carboplatin, and paclitaxel and other combination therapies | |
| MX2023014899A (es) | Nuevos conjugados que comprenden fosfoantígenos y su uso en terapia. | |
| MX2019000179A (es) | Combinacion de terapias para tratar el cancer. | |
| TW200719903A (en) | Compositions for the treatment of neoplasms | |
| SG10201708886RA (en) | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER | |
| ZA202213322B (en) | Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting | |
| MX2022011635A (es) | Radioinmunoconjugados dirigidos a fgfr3 y usos de estos. | |
| WO2021202830A3 (en) | Hsp90-binding conjugates and formulations thereof | |
| PH12021552326A1 (en) | Combinations of iadademstat for cancer therapy | |
| PH12021550323A1 (en) | Dendrimer formulations |